User profiles for R.E. Coleman

Robert Coleman

University of Sheffield
Verified email at sheffield.ac.uk
Cited by 75799

Clinical features of metastatic bone disease and risk of skeletal morbidity

RE Coleman - Clinical cancer research, 2006 - AACR
Coleman: In this data set, we don't have CA15-3, so we're limited to an analysis in prostate
cancer, where obviously PSA was measured regularly. There is literature comparing bone …

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

RE Coleman - Cancer treatment reviews, 2001 - Elsevier
Metastatic bone disease develops as a result of the many interactions between tumour cells
and bone cells. This leads to disruption of normal bone metabolism, with the increased …

Skeletal complications of malignancy

RE Coleman - … International Journal of the American Cancer …, 1997 - Wiley Online Library
The skeleton is the most common organ to be affected by metastatic cancer, and tumors
arising from the breast, prostate, thyroid, lung, and kidney possess a special propensity to …

The clinical course of bone metastases from breast cancer

RE Coleman, RD Rubens - British journal of cancer, 1987 - nature.com
RE Coleman & RD Rubens … Preliminary results show that prediction of objective response
within 3-4 weeks of starting treatment is possible (Coleman et al., unpublished data). Morbidity …

A tabulated summary of the FDG PET literature

…, DHS Silverman, RE Coleman… - Journal of nuclear …, 2001 - Soc Nuclear Med
… Appendix A gives details on the way in which literature was searched and analyzed, and
Appendix B reports some alternate approaches to summarizing the data. The average FDG …

Recommendations on the use of 18F-FDG PET in oncology

…, VJ Lowe, GH Lyman, RE Coleman… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The rationale was to develop recommendations on the use of 18 F-FDG PET in breast,
colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, …

[BOOK][B] The master plan of evangelism

RE Coleman - 2006 - books.google.com
… world evangelization in our generation as Robert Coleman’s The Master Plan of Evangelism…
Coleman has gone back to the Bible and has asked one critical question: What was Christ’s …

Use of florbetapir-PET for imaging β-amyloid pathology

…, ML Flitter, MJ Krautkramer, HF Kung, RE Coleman… - Jama, 2011 - jamanetwork.com
… Dr Coleman reported being on the medical advisory board for General Electric
Healthcare from 2003-2008; being a consultant for General Electric Healthcare from 2003-2008; …

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

…, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman… - The Lancet, 2007 - thelancet.com
Background Early improvements in disease-free survival have been noted when an aromatase
inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal …

Clinical applications of PET in oncology

EM Rohren, TG Turkington, RE Coleman - Radiology, 2004 - pubs.rsna.org
Positron emission tomography (PET) provides metabolic information that has been documented
to be useful in patient care. The properties of positron decay permit accurate imaging of …